SCHEMBL6288136

SCHEMBL6288136

CCc1cc2c(OCC(=O)OCc3ccccc3)c3ccccc3cc2n1Cc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 3/20 0.40
PLA2G10 O15496 2/20 0.40
PLA2G1B P04054 2/20 0.40
PLA2G2E Q9NZK7 2/20 0.40
PLA2G2D Q9UNK4 2/20 0.40
PLA2G5 P39877 1/20 0.40
PLA2G2F Q9BZM2 1/20 0.40
LMNA P02545 3/20 0.39
KDM4E B2RXH2 3/20 0.39
MAPT P10636 3/20 0.39
GAA P10253 2/20 0.39
PKM P14618 2/20 0.39
MTNR1A P48039 3/20 0.39
MTNR1B P49286 3/20 0.39
POLB P06746 1/20 0.38
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TSHR P16473 2/20 0.38
TP53 P04637 1/20 0.38
MEN1 O00255 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6284230 0.93 TSHR (0.43) PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D
SCHEMBL6279125 0.79 MTNR1A (0.44) PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D
SCHEMBL6285078 0.78 PLA2G2A (0.60) PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D
SCHEMBL8033789 0.72 ALDH1A1 (0.47) PLA2G2ALMNAKDM4EMAPTGAA
SCHEMBL3205580 0.71 MEN1 (0.45) PLA2G2ALMNAKDM4EMAPTGAA
SCHEMBL5160095 0.71 PLA2G2A (0.52) PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D
SCHEMBL6283147 0.71 PLA2G2A (0.61) PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D
SCHEMBL20792942 0.70 CASP3 (0.52) LMNAKDM4EMAPTGAAPKM
SCHEMBL25136 0.70 MTNR1B (0.60) PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D
SCHEMBL8023979 0.69 MTNR1A (0.46) PLA2G2APLA2G1BLMNAMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930123-B2 sPLA2 inhibitors ELI LILLY AND COMPANY (US) 2005-08-16 US disclosed
US-20040059130-A1 Spla2 inhibitors BEIGHT DOUGLAS WADE (US) 2004-03-25 US disclosed
EP-1349832-A2 SUBSTITUTED BENZOINDOLES AS SPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 2003-10-08 EP disclosed
WO-2002050028-A2 SUBSTITUTED BENZOINDOLES AS SPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040059130-A1 Spla2 inhibitors F2RL1, SPINT2, PLAAT2 PLA2G2A 31/4885PLA2G10 28/4885PLA2G1B 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.